This inventor holds 7 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: New York University, Puretech Health, LLC, Puretech Lyt, Inc.. Active years: 2019-2026.
Company Filing History:
6 out of 1,726 
4 out of 9 
2 out of 7 Years Active: 2019-2026
Title: Aleksandra Filipovic: Innovator in Immunotherapeutic Antibodies
Introduction
Aleksandra Filipovic is a prominent inventor based in London, GB, recognized for her significant contributions to the field of immunotherapy. With a portfolio of five patents to her name, she has been at the forefront of developing novel antibodies that target specific pathways in the immune system, positioning her as a leader in her field.
Latest Patents
Among Filipovic's latest patents are innovative antibodies targeting the delta-1 chain of the γδ T cell receptor. These antibodies are designed to modulate the bioactivity of γδ T cells, providing therapeutic avenues for diseases that are characterized by γδ T cell activation, including solid tumors. Another noteworthy patent involves anti-Galectin-9 antibodies, which are essential for inhibiting a signaling pathway mediated by Galectin-9. These antibodies have potential applications in diagnosing and treating autoimmune diseases and various cancers linked with Galectin-9 expression.
Career Highlights
Filipovic's career has been marked by her association with leading institutions such as New York University and PureTech Health, LLC. Her work in these organizations has furthered her research in antibody development, showcasing her commitment to addressing complex health challenges through innovative scientific solutions.
Collaborations
Throughout her career, Aleksandra has collaborated with notable colleagues, including Shohei Koide and George Miller. These partnerships have played a critical role in advancing her research and have contributed to her success in the field of patentable inventions within immunotherapy.
Conclusion
Aleksandra Filipovic’s innovative work in antibody development illustrates her dedication to enhancing therapeutic approaches for cancer and autoimmune diseases. Her patents demonstrate a profound understanding of immunology, and her collaborative efforts signal a bright future for continued innovations in medical treatment. As the demand for effective therapies grows, Filipovic stands out as a pivotal figure in the evolution of immunotherapeutic strategies.